DE

latest development

News & Events

Thursday, June 13, 2024
The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and...
Wednesday, May 29, 2024
FinanzNachrichten provides financial news and updates specifically related to Vidac Pharma Holdings PLC. It covers the company's stock performance, recent financial news, market analysis, and any significant corporate announcements. The page serves...
Wednesday, May 29, 2024
Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since...
Thursday, May 09, 2024
There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did not persist in 2024. Tough refinancing conditions have been holding the market back, according to the...
Monday, April 29, 2024
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for...
Monday, April 22, 2024
UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a...
Wednesday, April 17, 2024
The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of...
Monday, April 08, 2024
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys...